论文部分内容阅读
目的：评价洛赛克治疗肝动脉化疗栓塞后胃区疼痛并发症的临床效果。材料和方法：９４例肝癌症人在肝动脉化疗栓塞术后出现左上腹或剑突下疼痛并服用洛塞克治疗，洛赛克使用剂量常规给于２０ｍｇ／ｄ，少数症状明显而顽固者可用４０ｍｇ／ｄ或者更多。结果：用洛赛克治疗后，所有病人症状均得到不同程度缓减或消失，其中显效者为９３．６％，有效者为６．４％，无效者为０，总有效率为１００％。结论：洛赛克对肝癌介入治疗后胃区疼痛有明显的治疗效果，是肝癌介入治疗有效的辅助治疗药物
OBJECTIVE: To evaluate the clinical efficacy of Losec in the treatment of pain after complications of hepatic arterial chemoembolization. Materials and Methods: 94 patients with liver cancer developed hepatocele or xiphoid pain after transcatheter arterial chemoembolization and were treated with Losec. Rousek administration dose was given to 20 mg/d. A few symptoms were obvious and inflexible were available. 40mg/d or more. RESULTS: After treatment with Losec, the symptoms of all patients were reduced or disappeared to varying degrees. Among them, 93.6% were effective, 6.4% were effective, 0 were ineffective, and 100% were effective. Conclusion: Losec has obvious therapeutic effect on gastric pain after interventional treatment of liver cancer. It is an effective adjuvant therapy for interventional treatment of liver cancer.